Pfizer Inc said on Monday it has started a mid-to-late-stage study testing its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to the virus. The company and its rivals, including Merck & Co Inc and Roche Holding AG, have been racing to develop the first antiviral pill for COVID-19.
Pfizer said it would study the drug, PF-07321332, in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic COVID-19 infection. The trial would test PF-07321332 with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.
Read the full article.
Pfizer Inc said on Monday it has started a mid-to-late-stage study testing its investigational oral antiviral drug, to be co-administered with HIV drug ritonavir, for the prevention of COVID-19 infection. https://t.co/Ymzzav4pQs
— Reuters Health (@Reuters_Health) September 27, 2021